China NT Pharma : RESIGNATION OF EXECUTIVE AND NON-EXECUTIVE DIRECTORS AND CHANGE OF CHIEF FINANCIAL OFFICER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011)

RESIGNATION OF EXECUTIVE AND NON-EXECUTIVE DIRECTORS

AND

CHANGE OF CHIEF FINANCIAL OFFICER

The board (the "Board") of directors (the "Directors") of China NT Pharma Group Company Limited (the "Company"), together with its subsidiaries (the "Group"), announce that with effect from 29 November 2019:

• Ms. Lou Jianying ("Ms. Lou") resigned as a non-executive Director of the Company;
• Mr. Wang Fei ("Mr. Wang") resigned as an executive Director and the chief financial officer of the Company (the "Chief Financial Officer"); and
• Ms. Fang Jing ("Ms. Fang") was appointed as the Chief Financial Officer.

RESIGNATION OF EXECUTIVE AND NON-EXECUTIVE DIRECTORS AND CHIEF FINANCIAL OFFICER

The Board would like to announce that with effect from 29 November 2019:

1. Ms. Lou has tendered her resignation as a non-executive Director due to her other work commitments assigned by Shanghai Jiao Da Onlly Co., Ltd..; and
2. Mr. Wang has tendered his resignation as an executive Director and the Chief Financial Officer due to his other work commitments;

Ms. Lou and Mr. Wang have confirmed to the Board that there is neither any disagreement with the members of the Board nor any matters relating to their resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

1

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board is pleased to announce that, with effect from 29 November 2019, Ms. Fang was appointed as the Chief Financial Officer.

The biographical details of Ms. Fang are set out below:

Ms. Fang Jing (方靖女士), aged 50, joined the Company on 27 May 2019 as the Chief Operating Officer. She was further appointed as the Chief Financial Officer on 29 November 2019 and is responsible for the supervision and management of financial matters and financial risks of the Group. Ms. Fang has obtained the professional qualification as Chinese accountant and has over 20 years of extensive experience in accounting, financial management and corporate management. Prior to joining the Company, from 1997 to 2019, Ms. Fang worked at Shanghai Zhangjiang (Group) Co., Ltd. and Shanghai Zhangjiang Hi-Tech Park Development Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock Code: 600895), both of which are located in the Shanghai Zhangjiang Hi-Tech Park, and served different positions successively including the group's external financial controller, general manager of the asset management department and administration director. Ms. Fang graduated from Shanghai Lixin Accounting and Finance College in 1990 with a bachelor's degree in economics. Ms. Fang obtained the senior technician qualification in the field of financial management from the Training Technical Instruction Center of China Vocational Skill Appraisal Management Center in 2012 and obtained the national registered practitioner qualification as "Enterprise Risk Manager" from the Asia Association of Risk and Crisis Management in 2013.

The Board would like to extend its appreciation to Ms. Lou and Mr. Wang for their valuable contributions to the Group during their tenure of office and to welcome Ms. Fang for taking up the new appointment.

By Order of the Board

China NT Pharma Group Company Limited

Ng Tit

Chairman

Hong Kong, 29 November 2019

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Patrick Sun, Mr. Tze Shan Hailson Yu and Dr. Hong Yan.

2